Micro Pharmaceuticals
Market Cap
₹1,489 ₹1,489 Cr.
P/E
32.75
PEG
2.02
PEG = P/E ÷ 5yr forward EPS CAGR
5yr forward EPS CAGR thesis · Base case

The thesis comes alive if organic growth, medical-representative productivity and Equitas integration progress broadly on schedule, with hospital cross-selling adding to the core branded-pharma engine.

The bull path requires faster hospital cross-selling, stronger representative productivity and new-product conversion; the bear path reflects integration delays, weaker organic growth and productivity shortfalls.

  • Jagsonpal Pharma
  • Bharat Parenterals
  • Lincoln Pharma

FAQs on Jagsonpal Pharmaceuticals Ltd. Shareprice

Jagsonpal Pharma has given better returns compared to its competitors.
Jagsonpal Pharma has grown at ~44.4% over the last 8yrs while peers have grown at a median rate of 13.56%

Jagsonpal Pharma is not expensive.
Latest PE of Jagsonpal Pharma is 33.64, while 3 year average PE is 40.13.
Also latest EV/EBITDA of Jagsonpal Pharma is 23.3 while 3yr average is 29.94.

Growth Table

  • Jagsonpal Pharmaceuticals Ltd.
  • Bharat Parenterals
  • Lincoln Pharma

Balance Sheet

  • Jagsonpal Pharmaceuticals Ltd.
  • Bharat Parenterals
  • Lincoln Pharma

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Jagsonpal Pharmaceuticals Ltd.
  • Bharat Parenterals
  • Lincoln Pharma

Cash Flow

  • Jagsonpal Pharmaceuticals Ltd.
  • Bharat Parenterals
  • Lincoln Pharma

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Jagsonpal Pharmaceuticals Ltd.
  • Bharat Parenterals
  • Lincoln Pharma

Quarterly Results

  • Jagsonpal Pharmaceuticals Ltd.
  • Bharat Parenterals
  • Lincoln Pharma

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*

FAQs on Jagsonpal Pharmaceuticals Ltd. Financials

Balance sheet of Jagsonpal Pharma is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Jagsonpal Pharma is increasing.
Latest net debt of Jagsonpal Pharma is -₹212.24 Crs as of Mar-26.
This is greater than Mar-25 when it was -₹257.46 Crs.

The profit is oscillating.
The profit of Jagsonpal Pharma is ₹45.48 Crs for TTM, ₹43.08 Crs for Mar 2026 and ₹55.36 Crs for Mar 2025.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Jagsonpal Pharma latest dividend payout ratio is 85.49% and 3yr average dividend payout ratio is 58.11%

Companies resources are majorly tied in miscellaneous assets

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech